PMC:7554011 / 9851-10810 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7554011","sourcedb":"PMC","sourceid":"7554011","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7554011","text":"Formula was prepared as per manufacturer’s instructions: 1 scoop of powder (approximately 4.5 g) was added to 30 mL of boiled cooled water. Two formulations were tested: Singulair® granules (4 mg) and Actavis® chewable tablets (5 mg) which were crushed prior to mixing (following reported practices (7)). For the direct administration scenario, formulations were tested in the simulated GI fluids without prior mixing with a vehicle. For the mixing with vehicle scenario, each sample was prepared by addition of the formulation to milk (25 mL; as previously investigated (12)), applesauce (15 g) or formula (5 mL), followed by mixing with a stainless-steel spatula. Mixing with formula was performed only for the Singulair® granules to mimic the in vivo study dosing scenario (17). The preparation technique procedure was time-controlled (less than 2 min were spent between preparation and dosing of the mixture), and the mixing was performed in exactly 30 s.","tracks":[{"project":"2_test","denotations":[{"id":"33051713-27704550-26791","span":{"begin":300,"end":301},"obj":"27704550"},{"id":"33051713-18296556-26792","span":{"begin":777,"end":779},"obj":"18296556"}],"attributes":[{"subj":"33051713-27704550-26791","pred":"source","obj":"2_test"},{"subj":"33051713-18296556-26792","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93eca8","default":true}]}]}}